BIOXYTRAN, INC. financials

BIXT CIK 0001445815

Source: EDGAR filings · Built 2026-06-19T00:33:23Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Working Capital -2.74M -1.93M -3.22M -3.37M -3.21M -1.95M
Net Debt 345.09K 895.85K 2.10M 2.00M 2.14M 896.71K
Return on Equity (ROE) 81.93% 132.07% 144.05% 75.01% 127.66% 130.97%
Return on Assets (ROA) -322.39% -1706.40% -3208.83% -666.73% -3379.78% -778.95%
Current Ratio 0.16× 0.00× 0.01× 0.08× 0.02× 0.14×
Debt-to-Equity -0.33× -0.50× -0.68× -0.70× -0.70× -0.48×
Cash Conversion Ratio 0.25× 0.16× 0.17× 0.73× 0.42× 0.43×
Accruals Ratio -2.42× -14.31× -26.53× -1.80× -19.57× -4.42×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Research and Development Expense 454.00K 112.34K 1.15M 1.28M 2.01M 544.52K
Operating Expenses 1.84M 2.22M 3.80M 2.44M 4.21M 1.27M
Operating Income (Loss) -1.84M -2.22M -3.80M -2.44M -4.21M -1.27M
Net Income (Loss) Attributable to Parent -2.12M -2.37M -4.47M -2.47M -4.03M -2.54M
Earnings Per Share, Basic $-0.02 $-0.02 $-0.03 $-0.02 $-0.04
Weighted Average Number of Shares Outstanding, Basic 91.84M 138.60M 133.97M 112.71M 106.25M
Earnings Per Share, Diluted $-0.02 $-0.02 $-0.03 $-0.02
Weighted Average Number of Shares Outstanding, Diluted 91.84M 138.60M 133.97M 112.71M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Assets, Current 513.47K 5.15K 26.09K 295.40K 72.36K 316.40K
Assets 658.55K 138.69K 139.38K 370.94K 119.29K 326.40K
Liabilities, Current 3.25M 1.93M 3.24M 3.67M 3.28M 2.27M
Liabilities 3.25M 1.93M 3.24M 3.67M 3.28M 2.27M
Stockholders' Equity Attributable to Parent -3.16M -1.94M
Common Stock, Shares, Outstanding 108.15M 86.78M 144.64M 123.35M 110.84M 97.45M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -526.46K -381.32K -775.38K -1.80M -1.70M -1.10M
Net Cash Provided by (Used in) Investing Activities -23.09K -28.19K -44.30K -32.25K -36.93K -10.00K
Net Cash Provided by (Used in) Financing Activities 1.05M 388.58K 550.36K 2.06M 1.76M 981.05K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (BIXT CIK 0001445815), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

ALLR

Allarity Therapeutics, Inc.

GIBO

GIBO HOLDINGS LIMITED

POSC

POSITRON CORPORATION